OKYO Pharma
OKYO on Nasdaq. Market value $77m.
Should I look at this?
We have not checked this company yet
This is not advice.
Who owns it
None of the long-term investors we follow own it. 19 funds in all.
Largest holders overall
- Woodline Partners LP$5m
- Stonepine Capital Management$1m
- Maven Securities$1mCut
- Balyasny Asset Management L.P.$870,894
- Opaleye Management$562,806New
- UBS Group AG$82,514Cut
- XTX Topco$56,654
- Choreo$49,883New
- Quantinno Capital Management LP$49,882New
- Cerity Partners$19,218
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
4 investors own more than 5%.
- Chernett JoreyPassive investor9.5%+1.7 ptsSince 31 December 2025
- Sirenia Capital Management LPPassive investorat least 7.7%(filed with 1 related holder)Since 31 March 2026
- Woodline Partners LPPassive investor7.0%Since 31 March 2026
- LAURA NATALIA MONICA FONDAPassive investor5.0%Since 22 July 2025
- Dauntless Investment Group, LLCPassive investorSold down below 5%Since 31 December 2025
- Point72 Asset Management, L.P.Passive investorSold down below 5%Since 31 March 2026
| Holder | Stake | Since | |
|---|---|---|---|
Chernett Jorey Passive investor | 9.5%+1.7 pts | 31 December 2025 | |
Sirenia Capital Management LP Passive investor | at least 7.7% (filed with 1 related holder) | 31 March 2026 | |
Woodline Partners LP Passive investor | 7.0% | 31 March 2026 | |
LAURA NATALIA MONICA FONDA Passive investor | 5.0% | 22 July 2025 | |
Dauntless Investment Group, LLC Passive investor | Sold down below 5% | 31 December 2025 | |
Point72 Asset Management, L.P. Passive investor | Sold down below 5% | 31 March 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 6 insiders bought $136,006 of shares on the open market.
- Patil Rajkumar V.Chief Scientific OfficerBought
- Date
- 27 July 2026
- Shares
- 3,363
- Price
- $1.49
- Value
- $5,011
- Dempsey Robert JohnCHIEF EXECUTIVE OFFICER, DirectorBought
- Date
- 22 July 2026
- Shares
- 15,000
- Price
- $1.54
- Value
- $23,085
- BRANCACCIO JOHN PDirectorBought
- Date
- 21 July 2026
- Shares
- 5,000
- Price
- $1.48
- Value
- $7,385
- JACOB GARY SCHIEF DEVELOPMENT OFFICER, DirectorBought
- Date
- 21 July 2026
- Shares
- 3,500
- Price
- $1.40
- Value
- $4,900
- Mantelli FlavioCHIEF MEDICAL OFFICERBought
- Date
- 21 July 2026
- Shares
- 20,000
- Price
- $1.40
- Value
- $28,000
- CERRONE GABRIELE MDirectorBought
- Date
- 21 July 2026
- Shares
- 22,500
- Price
- $1.45
- Value
- $32,625
- CERRONE GABRIELE MDirectorBought
- Date
- 20 July 2026
- Shares
- 25,000
- Price
- $1.40
- Value
- $35,000
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 27 July 2026 | Patil Rajkumar V. Chief Scientific Officer | Bought | 3,363 | $1.49 | $5,011 |
| 22 July 2026 | Dempsey Robert John CHIEF EXECUTIVE OFFICER, Director | Bought | 15,000 | $1.54 | $23,085 |
| 21 July 2026 | BRANCACCIO JOHN P Director | Bought | 5,000 | $1.48 | $7,385 |
| 21 July 2026 | JACOB GARY S CHIEF DEVELOPMENT OFFICER, Director | Bought | 3,500 | $1.40 | $4,900 |
| 21 July 2026 | Mantelli Flavio CHIEF MEDICAL OFFICER | Bought | 20,000 | $1.40 | $28,000 |
| 21 July 2026 | CERRONE GABRIELE M Director | Bought | 22,500 | $1.45 | $32,625 |
| 20 July 2026 | CERRONE GABRIELE M Director | Bought | 25,000 | $1.40 | $35,000 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
OKYO Pharma doesn’t file a US annual report (10-K), so we haven’t checked it.
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.